37 results about "Bordetella sp" patented technology

The invention discloses a fungicide for removing and/ or degrading polycyclic aromatic hydrocarbon and application thereof. The invention provides a fungicide of which the active ingredients are (Rhodococcus sp.) LU3 CGMCC No.3610, (Microbacterium sp.) LU1 CGMCC No.3581, (Ochrobacterium sp.) LU2CGMCC NO.3582 and (Bordetella sp.) LU4 CGMCC No.3611. The experiment of the invention shows: after four weeks, the strainaway rate of 16 types of polycyclic aromatic hydrocarbon in soil added with the fungicide is averagely improved by 30% if being compared with that of soil which is not added with the fungicide, wherein the strainaway rate of six types of low-cyclic (two/three cyclic) polycyclic aromatic hydrocarbon is averagely improved by 26%, and the stainaway rate of ten types of middle and high cyclic (more than four cycle) polycyclic aromatic hydrocarbon is averagely improved by 32%.

An immunogenic composition comprising a recombinant protein comprising a Bordetella CyaA, or a fragment thereof, and a peptide that corresponds to a tumor antigen is provided as a cancer treatment. Methods of treatment with this immunogenic composition are also provided. In an embodiment, the therapeutic composition is a treatment for melanoma, and comprises epitopes from the HLA*0201 epitope. These epitopes include Tyr or GnT-V, and are present in the recombinant proteins CyaA-E5-Tyr and CyaA-E5-GnT-V.

Diagnostic testing and immunomonitoring that uses genetically detoxified Bordetella pertussis CyaA as a delivery system are effective in tracking any immune responses, such as those generated by infectious and non-infectious diseases, or vaccinations, for example. T cells previously stimulated by a given antigen can be restimulated in vitro by the same antigen fused or chemically coupled to CyaA or a fragment thereof. The invention includes diagnostic tests and immunomonitoring for tuberculosis by providing a delivery system, which can deliver the M. tuberculosis immunodominant proteins ESAT-6 and CFP-10, to human cells and non-human animal cells, such as cattle. In addition, fusion proteins between CyaA and cancer antigens are also provided as diagnostic tests and immunomonitoring systems for cancers, such as melanoma.

The present application relates to immunogenic compositions comprising a mixture of Bordetella (e.g., B. pertussis) antigens and an oil in water nanoemulsion. In particular, the invention provides immunogenic compositions comprising nanoemulsion and a combination of Bordetella (e.g., B. pertussis) antigens that have different functions, for example, combinations including B. pertussis adherence factors (adhesins), B. pertussis toxins or B. pertussis virulence factors. Vaccines, methods of treatment, uses of and processes to make a pertussis or whooping cough vaccine are also described. Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications.

The invention relates to a biological synergic microbial agent SY-CD-B and applications thereof in coking wastewater treatment. The biological synergic microbial agent is prepared by mixing six screened bacteria that are pseudomonas sp., acinetobacter sp., bordetella sp., klebsiella sp., bacillus magterium and bacillus subtilis according to a fermentation broth volume ratio of 5-50:1-5:3-15:2-20:2-20:2-20, centrifuging and diluting the bacteria with an inorganic salt culture liquid. By utilization of the biological synergic microbial agent and by combining a mixed type active sludge system, the COD concentration of biochemical treatment effluent is reduced, and no extra equipment investment is added. The biological synergic microbial agent is suitable for biochemical treatment of coking wastewater of water of various kinds of quality, and largely reduces the treatment cost.

The invention provides a method for manufacturing a quinclorac solid degrading inoculant, and belongs to the technical field of microorganisms. The method includes the steps that 1, preparation, pH adjustment and sterilization of a medium are conducted; 2, bordetella preserved on a bevel is inoculated, and shake cultivation is carried out to obtain liquid seeds; 3, the liquid seeds are inoculated in a culture medium containing wheat bran, corn straw powder and activated carbon, and are cultured in a constant-temperature culture box in a sealed mode to obtain a target product. The organophosphorus pesticide degrading inoculant produced through the technology has the advantages of being low in product cost and environmentally friendly, and the inoculant can efficiently degrade organophosphorus pesticide residues on the surfaces of plants and in soil. Besides, physical and chemical properties and biological characters of the soil can be improved, soil fertility is improved, immunity of crops can be enhanced, intrusion of bacteria is prevented, and the inoculant particularly has a good prevention function on soil-borne diseases and the continuous cropping barrier. Thus, crop growth is promoted, the agricultural yield is increased, quality of agricultural products is improved, and production cost is reduced.

The invention relates to a 6-aminopenicillanic acid (6-APA) degrading bacterium and a screening method thereof. Particularly, the invention relates to a strain of 6-APA degrading bacterium Bordetella sp.L2, which is preserved in China General Microbiological Culture Collection Center (CGMCC) on October 18, 2012, with the preservation number of CGMCC No. 6691; and the GenBank registration number of the 16S rRNA gene sequence of the 6-APA degrading bacterium Bordetella sp.L2 is HQ840720. The 6-APA degrading bacterium Bordetella sp.L2 is an aerobic bacillus brevis; and when the pH value is 8.0, the 6-APA degradation rate of the 6-APA degrading bacterium Bordetella sp.L2 is 28%. The strain achieves higher 6-APA degradation capability and has a practical significance and an important engineering application value for treatment of waste water containing 6-APA cephalosporin.

The invention relates to a strain of Bordetella sp. and the application in the preparation of cholesterol oxidase and cholest-4-ene-3-dione. The bacteria strain is Bordetella sp. B4 CGMCC No.2229, which is capable of synthesizing extracellular cholesterol oxidase and transforming cholesterol into cholest-4-ene-3-dione. The invention is characterized in short fermentation time and high enzyme production activity; the activity of extracellular enzyme can reach 2000U/L, which reaches or exceeds international leading level.

An immunogenic composition comprising a recombinant protein comprising a Bordetella CyaA, or a fragment thereof, and a peptide that corresponds to a tumor antigen is provided as a cancer treatment. Methods of treatment with this immunogenic composition are also provided. In an embodiment, the therapeutic composition is a treatment for melanoma, and comprises epitopes from the HLA*0201 epitope. These epitopes include Tyr or GnT-V, and are present in the recombinant proteins CyaA-E5-Tyr and CyaA-E5-GnT-V.

The present invention provides a vaccine production strain of Bordetella bronchiseptica that produces a pertussis toxin in high yield. The present invention provides a method for creating a Bordetella bronchiseptica cell line which produces a Bordetella pertussis toxin comprising the steps of introducing a plasmid containing a DNA encoding antibiotic resistance into a Bordetella bronchiseptica strain, selecting for isolates in which the DNA encoding antibiotic resistance is recombinantly incorporated into the chromosome in place of the Bordetella bronchiseptica toxin gene, introducing a plasmid containing DNA encoding subunits of the Bordetella pertussis toxins into the Bordetella bronchiseptica isolates; and, selecting for isolates in which DNA encoding Bordetella pertussis toxin subunit is recombinantly incorporated into the chromosome, the resulting cells producing the Bordetella pertussis toxin. The present invention further provides a method for creating a Bordetella bronchiseptica cell line which produces a Bordetella pertussis toxin and does not express filamentous hemagglutinin.

The present disclosure provides methods for determining whether a patient exhibiting pertussis-like symptoms will benefit from treatment, with therapeutic agents that inhibit Bordetella holmesii. These methods are based on detecting Bordetella pertussis, Bordetella parapertussis, and Bordetella holmesii in a biological sample by assaying for the presence of the IS481, IS 1001, and hIS1001 target repeat elements, respectively. Kits for use in practicing the methods are also provided.

The invention relates to a composite growth promoter. The microbial agent contains Bacillus subtilis, Bacillus amyloliquefaciens, Bordetella sp., Sinorhizobium sp., Pseudomonas alcaligenes, Nitrobacteriaceae, actinomycete, Sporotrichum thermophile, potassium aspartate and gibberellin. The growth promoter provided by the invention can be used for improving agronomic characters of tobacco such as plant height, stem girth, maximum leaf length, maximum leaf width and effective number of leaves; the growth promoter can also be used for improving the accumulation of amount of dry matters of the tobacco in parts such as roots, stems, leaves and the like; and the composite growth promoter provided by the invention can be used for improving the quality of growth of the tobacco.

Diagnostic testing and immunomonitoring that uses genetically detoxified Bordetella pertussis CyaA as a delivery system are effective in tracking any immune responses, such as those generated by infectious and non-infectious diseases, or vaccinations, for example. T cells previously stimulated by a given antigen can be restimulated in vitro by the same antigen fused or chemically coupled to CyaA or a fragment thereof. The invention includes diagnostic tests and immunomonitoring for tuberculosis by providing a delivery system, which can deliver the M. tuberculosis immunodominant proteins ESAT-6 and CFP-10, to human cells and non-human animal cells, such as cattle. In addition, fusion proteins between CyaA and cancer antigens are also provided as diagnostic tests and immunomonitoring systems for cancers, such as melanoma.

The present disclosure is directed to a method for cultivating a Bordetella species, comprising: cultivating a Bordetella species under aerobic conditions in a liquid culture medium; and maintaining apH of the liquid culture medium by using a strong acid, such as nitric acid, or using a first and second acid, wherein the first acid is an inorganic acid that dissociates essentially completely in water, such as nitric acid, hydrochloric acid or sulfuric acid, and wherein the second acid is an inorganic acid having an acid dissociation constant (pKa) of greater than 1, such as phosphoric acid. Methods for increasing the yield of Bordetella fimbrial agglutinogen 2 and fimbrial agglutinogen 3 (FIM2/3) in a supernatant fraction from a Bordetella culture are also provided.

The invention discloses a microbial agent used for degrading quinclorac herbicides. The microbial agent takes several strains of bordetella, arthrobacterium, bacillus megatherium, burkholderia cepacia, ochrobactrum anthropi, pseudomonas, alcaligenes faecalis, aspergillus niger and neurospora and cellulase, amylase, protease, lipase and a biological accelerating agent as raw materials, and fermented solutions obtained after the several strains of the bordetella, the arthrobacterium, the bacillus megatherium, the burkholderia cepacia, the ochrobactrum anthropi, the pseudomonas, the alcaligenes faecalis, the aspergillus niger and the neurospora undergo fermentation culture are mixed to form a mixed fermented solution, after thalli are collected by centrifugation from the mixed fermented solution, skimmed milk and sucrose are added, freeze drying is performed, and then, the thalli are compounded with the cellulase, the amylase, the protease, the lipase and the biological accelerating agentto obtain the microbial agent.

This invention provides a composition of at least one Bordetella antigen and an effective adjuvant amount of interleukin-12 (IL-12), and uses thereof as a vaccine against Bordetella infection. Methods for using IL-12 as an adjuvant in combination with vaccines against Bordetella are also provided.

Compositions and methods for the detection and diagnosis of Bordetella pertussis are disclosed. Provided are antibodies, or antigen binding fragment thereof, specific for tracheal colonization factor A (TcfA). Also provided are compositions comprising an anti-TcfA antibody of the instant invention and a carrier; and methods for inhibiting, treating, and/or preventing pertussis and/or a B. pertussis infection in a subject in need thereof are provided, comprising administering an anti-TcfA antibody of the instant invention to the subject.